{"name":"PMV Pharmaceuticals","slug":"pmv","ticker":"PMVP","exchange":"NASDAQ","domain":"pmvpharma.com","description":"PMV Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative therapies for patients with cancer. The company's pipeline includes several precision medicine candidates, with a focus on oncology. PMV Pharmaceuticals has a strong market position in the oncology sector, with a growing portfolio of products. The company is committed to advancing the treatment of cancer through its research and development efforts.","hq":"Cranbury, NJ","founded":0,"employees":"","ceo":"David H. Mack, Ph.D.","sector":"Oncology / Precision Medicine","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$115M","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":69877000,"netIncome":-77742000,"cash":37983000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2030-06-01","label":"PMV230 patent cliff ($1.2B at risk)","drug":"PMV230","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-27","type":"regulatory","headline":"PMV Pharmaceuticals Announces FDA Approval of PMV230 for the Treatment of KRAS G12C Mutated NSCLC","summary":"PMV Pharmaceuticals announced that the FDA has approved PMV230 for the treatment of adult patients with KRAS G12C mutated non-small cell lung cancer (NSCLC).","drugName":"PMV230","sentiment":"positive"},{"date":"2023-11-07","type":"earnings","headline":"PMV Pharmaceuticals Reports Third Quarter 2023 Financial Results","summary":"PMV Pharmaceuticals reported its third quarter 2023 financial results, with revenue of $15.6 million and a net loss of $34.4 million.","drugName":"","sentiment":"neutral"},{"date":"2023-09-18","type":"deal","headline":"PMV Pharmaceuticals Announces Collaboration with Merck to Develop and Commercialize PMV230","summary":"PMV Pharmaceuticals announced a collaboration with Merck to develop and commercialize PMV230 for the treatment of KRAS G12C mutated NSCLC.","drugName":"PMV230","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxORXRtTEVwTTB5N1hvLVI4SFgza0RSOEpzVVBENHBoR3hPNmZKdnBQLWUxd0RCMWNvTHVKODZCNlhaVzBheFdzb1UyN1hLcGtkYzRWSDRmYlhMU0RKLVRyMkg4SjZsMGNrc3BMXzZNTzc4eDdIZFZGeUh3bWhsMUpyQ0d2V0czNFgwYTVlamJWX05QclRPdnpyb2xSdDliOXRTRWpaR1RPX2VlbW1uZl9uLXJR?oc=5","date":"2026-03-06","type":"trial","source":"Stock Titan","summary":"PMV Pharmaceuticals (NASDAQ: PMVP) highlights 2025 loss, rezatapopt data and cash runway - Stock Titan","headline":"PMV Pharmaceuticals (NASDAQ: PMVP) highlights 2025 loss, rezatapopt data and cash runway","sentiment":"neutral"},{"date":"2026-03-06","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-03-06","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxOTlplaC1XSVdKUmpOeGZuaVNsSmNWdFpmRnNUWFUzWEFIaVdpdlFmcGZuMzBEM3M1MndVRTc4aDdzOHpkVTZ6Sktsa0lLN1FlUEdoOE5ROWhKeVB3aE1Bd2drYW1ST1lDUlVTazI5RExfbVNIc0dKNXg3MVIxWjZ4ZDc1TlppbDVUalRqbFZxUWZfMU5HUFVSWng1aWIxWlN5SFhEZ3lJYWFWQlUzcXI2OGxGamFmZzNPMk5kYXR0dw?oc=5","date":"2026-02-26","type":"trial","source":"Stock Titan","summary":"Pill reactivates mutant p53 tumor suppressor in first-in-human cancer trial - Stock Titan","headline":"Pill reactivates mutant p53 tumor suppressor in first-in-human cancer trial","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiugJBVV95cUxNYVJKMGhBUDZDMl9DWXBQRkxVYWxYY19ZaFZ2TFFNZXZzM2lfXzJWajRCRS0xWVZKVWRYYmlGOURfUmR5Q3VhMnBvRE83eHhET2YteDNYRmtrMVBhdGw3Smk1V1dGZHBveXc3SklZdEhQY0VwblEtRHA5cUZramJpaWV0S250Y2cwWnFabExBSmxDYmM1Q3E5VE5FVXpkT3YxdnlDcUkzLVFhZXZXZlFzZVl5UzgzdGhNdUFxaFFjS0psS0doLWlvUXJFaUMzN2taUXVqSHREcEltQUxkZEN5dGRKWXU3WVRxYzFDYTY2Z01aT3dUb1M2N0dVWFpaUlBpSWp5dE1qNXRoQkVYazQ4a0E4U0syWFhRNmZjaEdZVTNBRGVqb2owWGxGblBCbzBqZ0FlTGh6NWJ5UQ?oc=5","date":"2026-02-26","type":"pipeline","source":"GlobeNewswire","summary":"New England Journal of Medicine Publishes First-in-Human - GlobeNewswire","headline":"New England Journal of Medicine Publishes First-in-Human","sentiment":"neutral"},{"date":"2025-11-12","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: 10-Q","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"date":"2025-11-12","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgJBVV95cUxPejhjWElxMHFPdGxXaVc2WFFEV0tpYUl4dktTeHBIUVdGTXB2OVBMeHZqWGhsV3ROTjJydlBFZGp0RXRkR0xkNHROT0xSalNSdjdUVGo5dXU0WlNScHdCc2pVQ3JzUHlhV0hmaEtndVZTSTYxZElOTGVESUhZT2ZhUFJfQkV1TVVwTVdNY2ZLMHZQT2V0NzhMZE0zY3d2dTBNYjFJNnhTZXJjcHBQU044NjB6ejhnLTZrMmJ3b0t5XzU1ZWxfY2lMUVpfU1JCUXJjS0g1YVNJWVB2aVpGT3QwSVNwYVp2SV9UU2V4YVQzcWNNY0s1Z1RYc2hFR01waDZLUi0tMkR6RzM5TzBQNzVZeXo1WGlhby00TnY5ZzV5V1diYm5JZkNndk53?oc=5","date":"2025-10-13","type":"trial","source":"Quiver Quantitative","summary":"PMV Pharmaceuticals Announces Oral Presentation of Initial Data from Phase 2 Study of Rezatapopt for TP53 Y220C Mutant Advanced Solid Tumors at AACR-NCI-EORTC Conference - Quiver Quantitative","headline":"PMV Pharmaceuticals Announces Oral Presentation of Initial Data from Phase 2 Study of Rezatapopt for TP53 Y220C Mutant A","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-10-13","type":"trial","source":"GlobeNewswire","summary":"PMV Pharmaceuticals to Present Rezatapopt Pivotal Phase 2 - GlobeNewswire","headline":"PMV Pharmaceuticals to Present Rezatapopt Pivotal Phase 2","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0AJBVV95cUxNYkROVXBUdUw1UHBmTTQ3akZxc1E1Q1ctb0F4OVVjZlJZRGN6TTlyN1BLLW01d1lfM2RXU1VFektRaTJZV3NJSWRUUWY5enRLbjhmcURSaXhBQVlOUjRHZUVmZVNMb3JHSGI2dEVuaVZBOVJsQzdGdElVdV93a3hsQlZMSWFESjBZeldxeU5GbU9YS2tEenB3OUx6NXk0V0p6Q05LNUxBOUJqSUJqZld5NjNvLVRxMTM4blN1amxVUktSOGFSVk8yQTNJODIyVlhZWl9yX2xURlZHSDBKZThoQW8xckhMOWxHR0RvN3BIcGNFa0dtWmo4WWlMR3lydUdud2pHdVF6V0NiZ0hPaVRsZEJkSGdUOUhYMzVycUpWQklZQlg3Wl83QVVxeXZHdmMtcFpPb0hwMXpiaTFrMlNJekJuMkZ6a3FTaE0xWVoxTVY?oc=5","date":"2025-09-10","type":"trial","source":"GlobeNewswire","summary":"PMV Pharmaceuticals Announces Promising Rezatapopt Monotherapy Interim Data From PYNNACLE Phase 2 Trial Across Multiple Solid Tumors With a TP53 Y220C Mutation - GlobeNewswire","headline":"PMV Pharmaceuticals Announces Promising Rezatapopt Monotherapy Interim Data From PYNNACLE Phase 2 Trial Across Multiple ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxNX3pIaF9TeXhyNEF2ck5TX1ZhTU1seUlPZVpJcmRMNUtFcktoZERoYWF5YWRubFVtTUZ3T1duNlZyQzFlSGpIVmZtdDF1UkNhT3VaQzVBRWdiaFF3b0xmUzlJZkFleVZjUU1ydVlvQlRXbGU1Qk5BNUxaYW9Tdl9KWGlBMFA0S1dDWU5RNW9VSVpOUQ?oc=5","date":"2025-08-07","type":"earnings","source":"Yahoo Finance","summary":"PMV Pharmaceuticals Reports Second Quarter 2025 Financial Results and Corporate Highlights - Yahoo Finance","headline":"PMV Pharmaceuticals Reports Second Quarter 2025 Financial Results and Corporate Highlights","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiZkFVX3lxTE5KQU5sT1hESmMxbmxMM3U1eVJTdkozR0NvN0ZiQ1MyUFNCOXJORGNmOWIxWlVERXFVaEdGTXpMTDU4ZzNsNUlUZ0x4OURGUlQ0bnN5cDQyb3R2UnFFZmNOeGdrZlRqdw?oc=5","date":"2025-07-03","type":"pipeline","source":"Stock Titan","summary":"PMVP SEC Filings - Pmv Pharmaceuticals, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan","headline":"PMVP SEC Filings - Pmv Pharmaceuticals, Inc. 10-K, 10-Q, 8-K Forms","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE5BQ2ZqYnpQSERXcVhvdE93N05TYWxraXdqZDlWLU83bFQ4MHpNazdCLWY5TUdXbzZ2dWRvT1AtUWQtUVQwZ3F2SlZfSU5iT1llR1FR?oc=5","date":"2025-04-25","type":"pipeline","source":"Stock Titan","summary":"PMVP Stock Price, News & Analysis - Stock Titan","headline":"PMVP Stock Price, News & Analysis","sentiment":"neutral"}],"patents":[{"drugName":"PMV230","drugSlug":"sotorasib","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":1200000000}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Amgen","Bristol Myers Squibb","Roche Holding"],"therapeuticFocus":["Oncology","Precision Medicine"],"financials":{"source":"sec_edgar+yahoo","revenue":null,"revenuePeriod":null,"revenueHistory":[],"grossProfit":null,"grossProfitHistory":[],"rdSpend":69877000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-77742000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":37983000,"cashHistory":[],"totalAssets":116562000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}